Literature DB >> 15851471

Platelet endothelial aggregation receptor 1 (PEAR1), a novel epidermal growth factor repeat-containing transmembrane receptor, participates in platelet contact-induced activation.

Nisha Nanda1, Ming Bao, Hanna Lin, Karl Clauser, Laszlo Komuves, Thomas Quertermous, Pamela B Conley, David R Phillips, Matthew J Hart.   

Abstract

The present study was designed to identify novel membrane proteins that signal during platelet aggregation. Because one putative mechanism for signaling by a membrane protein involves phosphorylation, we used oligonucleotide-based microarray analyses and mass spectrometric proteomics techniques to specifically discover membrane proteins and also identify those proteins that become phosphorylated on tyrosine, threonine, or serine residues upon platelet aggregation. Surprisingly, both techniques converged to identify a novel membrane protein we have termed PEAR1 (platelet endothelial aggregation receptor 1). Sequence analysis of PEAR1 predicts a type-1 membrane protein, 15 extracellular epidermal growth factor-like repeats, and multiple cytoplasmic tyrosines. Analysis of the tissue distribution of PEAR1 showed that it was most highly expressed in platelets and endothelial cells. Upon platelet aggregation induced by physiological agonists, PEAR1 became phosphorylated on tyrosine (Tyr-925), and serine (Ser-953 and Ser-1029) residues. PEAR1 tyrosine phosphorylation was blocked by eptifibatide, an alpha(IIb)beta(3) antagonist, which inhibits platelet aggregation. Immune clustering of PEAR1 resulted in PEAR1 phosphorylation. Aggregation-induced PEAR1 tyrosine phosphorylation lead to the subsequent association with the ShcB adaptor protein. Platelet proximity induced by centrifugation also induced PEAR1 tyrosine phosphorylation, a reaction not inhibited by eptifibatide. These data suggest that PEAR1 is a novel platelet receptor that signals secondary to alpha(IIb)beta(3)-mediated platelet-platelet contacts.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15851471     DOI: 10.1074/jbc.M413411200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  48 in total

Review 1.  Canonical and non-canonical Notch ligands.

Authors:  Brendan D'Souza; Laurence Meloty-Kapella; Gerry Weinmaster
Journal:  Curr Top Dev Biol       Date:  2010       Impact factor: 4.897

Review 2.  Platelet genomics and proteomics in human health and disease.

Authors:  Iain C Macaulay; Philippa Carr; Arief Gusnanto; Willem H Ouwehand; Des Fitzgerald; Nicholas A Watkins
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

Review 3.  Proteomic approaches to dissect platelet function: Half the story.

Authors:  Dmitri V Gnatenko; Peter L Perrotta; Wadie F Bahou
Journal:  Blood       Date:  2006-08-22       Impact factor: 22.113

Review 4.  Minding the gaps to promote thrombus growth and stability.

Authors:  Lawrence F Brass; Li Zhu; Timothy J Stalker
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

5.  Whole exome sequence analysis of serous borderline tumors of the ovary.

Authors:  Jeff Boyd; Biao Luo; Suraj Peri; Beth Wirchansky; Lucinda Hughes; Caitlin Forsythe; Hong Wu
Journal:  Gynecol Oncol       Date:  2013-06-14       Impact factor: 5.482

Review 6.  The many facets of Notch ligands.

Authors:  B D'Souza; A Miyamoto; G Weinmaster
Journal:  Oncogene       Date:  2008-09-01       Impact factor: 9.867

7.  Targeted deep sequencing of the PEAR1 locus for platelet aggregation in European and African American families.

Authors:  Ali R Keramati; Lisa R Yanek; Kruthika Iyer; Margaret A Taub; Ingo Ruczinski; Diane M Becker; Lewis C Becker; Nauder Faraday; Rasika A Mathias
Journal:  Platelets       Date:  2018-03-19       Impact factor: 3.862

8.  Synthetic glycopolymers and natural fucoidans cause human platelet aggregation via PEAR1 and GPIbα.

Authors:  Caroline Kardeby; Knut Fälker; Elizabeth J Haining; Maarten Criel; Madelene Lindkvist; Ruben Barroso; Peter Påhlsson; Liza U Ljungberg; Mattias Tengdelius; G Ed Rainger; Stephanie Watson; Johannes A Eble; Marc F Hoylaerts; Jonas Emsley; Peter Konradsson; Steve P Watson; Yi Sun; Magnus Grenegård
Journal:  Blood Adv       Date:  2019-02-12

Review 9.  Novel antiplatelet agents in the prevention of cardiovascular complications--focus on ticagrelor.

Authors:  Margaret M Marczewski; Marek Postula; Dariusz Kosior
Journal:  Vasc Health Risk Manag       Date:  2010-06-01

Review 10.  Genetic dissection of platelet function in health and disease using systems biology.

Authors:  Wadie F Bahou
Journal:  Hematol Oncol Clin North Am       Date:  2013-04-09       Impact factor: 3.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.